Skip to main content
Erschienen in: Der Internist 12/2014

01.12.2014 | Arzneimitteltherapie

Neue Antibiotika vor Zulassung

Ende des Innovationsstaus?

verfasst von: Prof. Dr. J.R. Bogner

Erschienen in: Die Innere Medizin | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die Entwicklung neuer Antibiotika kann die Behandlung von Infektionen mit multiresistenten Erregern erleichtern und verbessern. Die starke Zunahme gramnegativer Problemkeime und ein Wandel in der Virulenz verlangen nach neuen Therapieansätzen.

Methode

Im vorliegenden Beitrag wird auf aktuell in klinischen Studienphasen befindliche Antibiotika gegen grampositive wie auch gramnegative Erreger und auf ein neues Medikament gegen Clostridien eingegangen.

Schlussfolgerung

In naher Zukunft wird eine Reihe wichtiger neuer Antibiotika zur Zulassung kommen.
Literatur
1.
Zurück zum Zitat Actavis (2014) Actavis announces positive topline results from the phase III program of ceftazidime-avibactam in patients with complicated intra-abdominal infections(cIAI). http://www.actavis.com/news/news/thomson-reuters/actavis-announces-positive-topline-results-from-th Actavis (2014) Actavis announces positive topline results from the phase III program of ceftazidime-avibactam in patients with complicated intra-abdominal infections(cIAI). http://​www.​actavis.​com/​news/​news/​thomson-reuters/​actavis-announces-positive-topline-results-from-th
2.
Zurück zum Zitat CNBC News (2014) Basilea initiates phase 1 combination study. Communication by Basilea. http://www.cnbc.com/id/101752624# CNBC News (2014) Basilea initiates phase 1 combination study. Communication by Basilea. http://​www.​cnbc.​com/​id/​101752624#
3.
Zurück zum Zitat Dalhoff A (2012) Resistance surveillance studies: a multifaceted problem – the fluoroquinolone example. Infection 40:239–262PubMedCrossRef Dalhoff A (2012) Resistance surveillance studies: a multifaceted problem – the fluoroquinolone example. Infection 40:239–262PubMedCrossRef
4.
Zurück zum Zitat Farrell DJ, Flamm RK, Sader HS et al (2013) Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011–2012). Antimicrob Agents Chemother 57:6305–6310PubMedCentralPubMedCrossRef Farrell DJ, Flamm RK, Sader HS et al (2013) Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011–2012). Antimicrob Agents Chemother 57:6305–6310PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Farrell DJ, Sader HS, Flamm RK et al (2014) Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents 43:533–539PubMedCrossRef Farrell DJ, Sader HS, Flamm RK et al (2014) Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents 43:533–539PubMedCrossRef
6.
Zurück zum Zitat Flamm RK, Sader HS, Farrell DJ et al (2014) Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis (im Druck) Flamm RK, Sader HS, Farrell DJ et al (2014) Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis (im Druck)
7.
Zurück zum Zitat Flanagan S, Fang E, Munoz KA et al (2014) Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy 34:891–900PubMedCrossRef Flanagan S, Fang E, Munoz KA et al (2014) Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy 34:891–900PubMedCrossRef
8.
Zurück zum Zitat Flanagan S, Minassian SL, Morris D et al (2014) Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother (im Druck) Flanagan S, Minassian SL, Morris D et al (2014) Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother (im Druck)
9.
Zurück zum Zitat Flanagan S, Passarell J, Lu Q et al (2014) Tedizolid population pharmacokinetics, exposure-response, and target attainment. Antimicrob Agents Chemother (im Druck) Flanagan S, Passarell J, Lu Q et al (2014) Tedizolid population pharmacokinetics, exposure-response, and target attainment. Antimicrob Agents Chemother (im Druck)
10.
Zurück zum Zitat Griffith DC, Loutit JS, Morgan EE et al (2014) A phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor RPX7009 in health adult subjects. 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2014, Barcelona Griffith DC, Loutit JS, Morgan EE et al (2014) A phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor RPX7009 in health adult subjects. 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2014, Barcelona
11.
Zurück zum Zitat Higgins PG, Stefanik D, Page MG et al (2012) In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii. J Antimicrob Chemother 67:1167–1169 Higgins PG, Stefanik D, Page MG et al (2012) In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii. J Antimicrob Chemother 67:1167–1169
12.
Zurück zum Zitat Hirsch EB, Ledesma KR, Chang KT et al (2012) In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 56:3753–3757PubMedCentralPubMedCrossRef Hirsch EB, Ledesma KR, Chang KT et al (2012) In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 56:3753–3757PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Wallstreet Journal (2014) Actelions neuartiges Antibiotikum Cadazolid erhält Einstufung als Qualified Infectious Disease Product (QIDP-Status) zur Behandlung von Clostridium-difficile-assoziierter Diarrhoe durch die FDA. http://www.wallstreet-online.de/nachricht/6606569-actelions-neuartiges-antibiotikum-cadazolid-einstufung-qualified-infectious-disease-product-qidp-status-behandlung-clostridium-difficile-assoziierter-diarrhoe-fda Wallstreet Journal (2014) Actelions neuartiges Antibiotikum Cadazolid erhält Einstufung als Qualified Infectious Disease Product (QIDP-Status) zur Behandlung von Clostridium-difficile-assoziierter Diarrhoe durch die FDA. http://​www.​wallstreet-online.​de/​nachricht/​6606569-actelions-neuartiges-antibiotikum-cadazolid-einstufung-qualified-infectious-disease-product-qidp-status-behandlung-clostridium-difficile-assoziierter-diarrhoe-fda
14.
Zurück zum Zitat Lemaire S, Tulkens PM, Van Bambeke F (2011) Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother 55:649–658PubMedCentralPubMedCrossRef Lemaire S, Tulkens PM, Van Bambeke F (2011) Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother 55:649–658PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Liapikou A, Cilloniz C, Mensa J et al (2014) New antimicrobial approaches to gram positive respiratory infections. Pulm Pharmacol Ther (im Druck) Liapikou A, Cilloniz C, Mensa J et al (2014) New antimicrobial approaches to gram positive respiratory infections. Pulm Pharmacol Ther (im Druck)
16.
Zurück zum Zitat Lubbert C, Becker-Rux D, Rodloff AC et al (2014) Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection 42:309–316PubMedCrossRef Lubbert C, Becker-Rux D, Rodloff AC et al (2014) Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection 42:309–316PubMedCrossRef
17.
Zurück zum Zitat Lucasti C, Hershberger E, Miller B et al (2014) Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 58:5350–5357PubMedCrossRef Lucasti C, Hershberger E, Miller B et al (2014) Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 58:5350–5357PubMedCrossRef
18.
Zurück zum Zitat Maseda E, Aguilar L, Gimenez MJ, Gilsanz F (2014) Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. Expert Rev Anti Infect Ther 12:1311–1324PubMedCrossRef Maseda E, Aguilar L, Gimenez MJ, Gilsanz F (2014) Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. Expert Rev Anti Infect Ther 12:1311–1324PubMedCrossRef
19.
Zurück zum Zitat Mima T, Kvitko BH, Rholl DA et al (2011) In vitro activity of BAL30072 against Burkholderia pseudomallei. Int J Antimicrob Agents 38:157–159PubMedCentralPubMedCrossRef Mima T, Kvitko BH, Rholl DA et al (2011) In vitro activity of BAL30072 against Burkholderia pseudomallei. Int J Antimicrob Agents 38:157–159PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Moran GJ, Fang E, Corey GR et al (2014) Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 14:696–705PubMedCrossRef Moran GJ, Fang E, Corey GR et al (2014) Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 14:696–705PubMedCrossRef
21.
Zurück zum Zitat Mushtaq S, Woodford N, Hope R et al (2013) Activity of BAL30072 alone or combined with beta-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters. J Antimicrob Chemother 68:1601–1608 Mushtaq S, Woodford N, Hope R et al (2013) Activity of BAL30072 alone or combined with beta-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters. J Antimicrob Chemother 68:1601–1608
22.
Zurück zum Zitat U.S. National Institutes of Health (2014) Registry of publicly and privately supported clinical trials. https://clinicaltrials.gov U.S. National Institutes of Health (2014) Registry of publicly and privately supported clinical trials. https://​clinicaltrials.​gov
23.
Zurück zum Zitat Nordmann P, Girlich D, Pypstra R et al (2014) Characterisation of beta-lactamase inhibition by AAI101, an extended-spectrum beta-lactamase inhibitor. 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2014, Barcelona Nordmann P, Girlich D, Pypstra R et al (2014) Characterisation of beta-lactamase inhibition by AAI101, an extended-spectrum beta-lactamase inhibitor. 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2014, Barcelona
24.
Zurück zum Zitat OnVista (2014) GNW-News: Basilea beginnt Phase-1-Kombinationsstudie mit ihrem gramnegativen Antibiotikum BAL30072 und Meropenem. http://www.onvista.de/news/gnw-news-basilea-beginnt-phase-1-kombinationsstudie-mit-ihrem-gramnegativen-antibiotikum-bal30072-und-meropenem-1007603 OnVista (2014) GNW-News: Basilea beginnt Phase-1-Kombinationsstudie mit ihrem gramnegativen Antibiotikum BAL30072 und Meropenem. http://​www.​onvista.​de/​news/​gnw-news-basilea-beginnt-phase-1-kombinationsstud​ie-mit-ihrem-gramnegativen-antibiotikum-bal30072-und-meropenem-1007603
25.
Zurück zum Zitat Rybak JM, Marx K, Martin CA (2014) Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance. Pharmacotherapy (im Druck) Rybak JM, Marx K, Martin CA (2014) Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance. Pharmacotherapy (im Druck)
26.
Zurück zum Zitat Sader HS, Farrell DJ, Castanheira M et al (2014) Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–2012). J Antimicrob Chemother 69:2713–2722 Sader HS, Farrell DJ, Castanheira M et al (2014) Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–2012). J Antimicrob Chemother 69:2713–2722
27.
Zurück zum Zitat Sader HS, Flamm RK, Jones RN (2013) Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010–2011. Antimicrob Agents Chemother 57:1982–1988PubMedCentralPubMedCrossRef Sader HS, Flamm RK, Jones RN (2013) Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010–2011. Antimicrob Agents Chemother 57:1982–1988PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Siala W, Mingeot-Leclercq MP, Tulkens PM et al (2014) Antibiotic activity against biofilms from Staphylococcus aureus clinical isolates: factors determining the activity of the investigational fluoroquinolone delafloxacin in comparison with daptomycin and vancomycin. Antimicrob Agents Chemother (im Druck) Siala W, Mingeot-Leclercq MP, Tulkens PM et al (2014) Antibiotic activity against biofilms from Staphylococcus aureus clinical isolates: factors determining the activity of the investigational fluoroquinolone delafloxacin in comparison with daptomycin and vancomycin. Antimicrob Agents Chemother (im Druck)
Metadaten
Titel
Neue Antibiotika vor Zulassung
Ende des Innovationsstaus?
verfasst von
Prof. Dr. J.R. Bogner
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Innere Medizin / Ausgabe 12/2014
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-014-3616-5

Weitere Artikel der Ausgabe 12/2014

Der Internist 12/2014 Zur Ausgabe

CME Zertifizierte Fortbildung

Hyponatriämie

Kongresse des BDI

BDI-Kongresse

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.